Global Mycoplasma Detection Service Market Strategic Research Report

Scope of the Report

The global Mycoplasma Detection Service market size is predicted to grow from US$ 657 million in 2025 to US$ 904 million in 2032; it is expected to grow at a CAGR of 4.5% from 2026 to 2032.

Mycoplasma Detection Service refers to outsourced laboratory testing services used to detect mycoplasma contamination in cell cultures, biological products, cell therapy materials, vaccines, research samples, and biopharmaceutical production environments. These services commonly use PCR, qPCR, culture-based methods, DNA staining, enzymatic detection, or validated rapid microbiological methods to identify contamination. Service providers usually offer sample receipt, nucleic acid extraction, testing, quality control, result interpretation, certificate issuance, and technical consultation. The service helps laboratories and manufacturers ensure cell line purity, avoid experimental failure, meet regulatory expectations, and reduce contamination risk in biologics, gene therapy, vaccine, and life science research workflows.

The industrial chain of Mycoplasma Detection Service includes upstream resources such as sample collection tubes, PCR reagents, qPCR instruments, culture media, DNA staining reagents, extraction kits, positive controls, negative controls, sterile consumables, laboratory information systems, and quality management tools. The midstream consists of sample registration, pretreatment, assay selection, nucleic acid amplification, culture verification, data analysis, quality review, report generation, and compliance documentation. Downstream users mainly include biopharmaceutical companies, cell therapy developers, vaccine manufacturers, cell banks, CROs, CDMOs, academic laboratories, diagnostic research institutions, and quality control departments. Related services include method validation, contamination investigation, routine monitoring, rapid release testing, troubleshooting, and long-term testing program support.

The market for Mycoplasma Detection Service is growing rapidly as biopharmaceutical manufacturing, cell therapy, gene therapy, vaccine development, and cell culture-based research place greater emphasis on contamination control and quality compliance. A key trend is the shift from traditional culture-based testing toward rapid PCR and qPCR services that shorten turnaround time and support batch release decisions. Customers are also paying more attention to method validation, regulatory documentation, sample traceability, sensitivity, specificity, and laboratory accreditation. In the coming years, providers with strengths in rapid molecular testing, GMP-compliant workflows, global sample logistics, and biopharmaceutical quality support are expected to gain competitive advantages. Overall, the industry is moving toward faster, more standardized, and more compliance-driven mycoplasma testing services.

This report presents a comprehensive overview of the global Mycoplasma Detection Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Culture-based Mycoplasma Detection
• PCR/qPCR Mycoplasma Detection
• Others

Segment by Service Purpose

• Product Release Testing
• Contamination Investigation Testing
• Regulatory Compliance Testing
• Others

Segment by Sample Type

• Cell Bank Testing
• Cell Culture Testing
• Others

Segment by Application

• Biopharmaceutical Companies
• Contract Research/Manufacturing Organizations (CROs/CMOs)
• Universities and Research Institutions
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mycoplasma Detection Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Biopharmaceutical Companies, Contract Research/Manufacturing Organizations (CROs/CMOs), Universities and Research Institutions evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact